Themis announces exclusive license and research collaboration agreement with MSD to develop vaccine candidates

22. August 2019

|In Portfolio News

|By eazee-designstudio

Themis announced today a research collaboration and exclusive license agreement with MSD for the discovery and development of undisclosed vaccine candidates using Themis’ measles virus vector-based platform. Under the terms of the agreement, Themis will develop vaccine candidates against an undisclosed disease target. MSD will provide research funding and make an equity investment in Themis. In addition, Themis will be eligible to receive development and sales milestone payments up to the potential value of approx. USD 200 million as well as royalties on approved products from the collaboration.